Get the Stockscreener App
4.46
0.89%
-0.04
After Hours:
4.54
0.08
+1.79%
Verastem Inc stock is traded at $4.46, with a volume of 1.81M.
It is down -0.89% in the last 24 hours and up +20.22% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$4.50
Open:
$4.52
24h Volume:
1.81M
Relative Volume:
0.75
Market Cap:
$391.92M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-1.3402
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+16.75%
1M Performance:
+20.22%
6M Performance:
-35.17%
1Y Performance:
-7.08%
1-Day Range:
$4.41
$4.74
1-Week Range:
$3.745
$4.74
52-Week Range:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.46 | 335.68M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem, Inc. Stock Hits New 52-Week Low at $3.43 - MarketsMojo
Verastem, Inc. Actuals & Estimates (NASDAQ:VSTM) - TradingView
Price to earnings forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
VSTM Forecast — Price Target — Prediction for 2027 - TradingView
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Price to book forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) insider sale notice: 21,492 shares reported for resale - Stock Titan
Verastem, Inc. Actuals & Estimates (GETTEX:2VSA) - TradingView
Enterprise value to revenue forward of Verastem, Inc. – GETTEX:2VSA - TradingView
2VSA Forecast — Price Target — Prediction for 2027 - TradingView
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Insider Monkey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Price to sales forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Price to book forward of Verastem, Inc. – GETTEX:2VSA - TradingView
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Verastem (VSTM) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Verastem Inc (VSTM) CEO Dan Paterson Sells 20,871 Shares - GuruFocus
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18.00 - GuruFocus
Verastem CFO Daniel Calkins sells $17,089 in company stock By Investing.com - Investing.com Australia
Form 4 Verastem Inc For: 24 June By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares By Investing.com - Investing.com South Africa
Verastem CEO Dan Paterson sells $87,240 in shares - Investing.com UK
Verastem CFO Daniel Calkins sells $17,089 in company stock - Investing.com
Verastem (VSTM) CEO sells 20,871 shares to cover RSU tax withholding - Stock Titan
Verastem (NASDAQ: VSTM) CFO sells 4,089 shares to cover RSU taxes - Stock Titan
VSTM Q1 2026 Earnings: EPS Beats Estimates by 2.19% as Pre-Revenue Biotech Advances Pipeline - dars.gov.et
VSTM Reiterates by BTIG -- Price Target Maintained at $18.00 - GuruFocus
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential - Investing.com
RBC Capital reiterates Verastem stock rating on G12D inhibitor potential By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $8 to $18 - Moomoo
Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated CancersSlideshow (NASDAQ:VSTM) 2026-06-24 - Seeking Alpha
H.C. Wainwright reiterates Verastem stock rating on drug trial data By Investing.com - Investing.com UK
VSTM Maintains Rating by Jefferies -- Price Target Lowered to $8 - GuruFocus
Verastem Inc (VSTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verastem (VSTM) Reports Promising Outcomes from Phase 1/2 Trial of VS-7375 - GuruFocus
Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375 - Moomoo
Verastem Advances VS-7375 with Promising Early Trial Data - TipRanks
Verastem stock falls despite early cancer drug trial data By Investing.com - Investing.com South Africa
Verastem stock falls despite early cancer drug trial data - Investing.com
Verastem posts VS-7375 data, reports anti-tumor activity at 400–900 mg QD and 93% CA19-9 drops in mPDAC - TradingView
Verastem (NASDAQ: VSTM) details VS-7375 KRAS G12D data and plans Phase 3 trials - Stock Titan
VERASTEMVS-7375 SAFETY PROFILE MAINLY LOW-GRADE GI EVENTS THAT DECREASE AFTER CYCLE 1 - Moomoo
Verastem's New Drug Shows Major Promise Against a Notorious Cancer Gene - BriefGlance
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verastem Inc Stock (VSTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paterson Dan | President and CEO |
Jun 22 '26 |
Sale |
4.18 |
20,871 |
87,241 |
591,242 |
| Calkins Daniel | Chief Financial Officer |
Jun 22 '26 |
Sale |
4.18 |
4,089 |
17,089 |
117,238 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):